Sorafenib as a potential strategy for refractory pulmonary arterial hypertension
In conclusion, sorafenib had favorable effects to improve symptoms and objective variables in patients with refractory PAH, with tolerable adverse events. Sorafenib is an alternative strategy for patients with refractory PAH. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - March 16, 2017 Category: Respiratory Medicine Source Type: research

XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblasts
In conclusion, this is the first study describing the involvement of XPLN in the regulation of SPARC. These findings may help uncover the regulatory mechanisms of the mTORC2-SPARC axis. The up-regulation of XPLN by HDAC inhibitors may be a novel therapeutic approach in patients with IPF. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - March 15, 2017 Category: Respiratory Medicine Source Type: research

Effect of angiotensin 2 receptor blockers on chronic obstructive lung disease mortality: A retrospective cohort study
Discussion ARBs use seems to be associated to a lower mortality in patients with COPD. Additional studies are needed to corroborate this finding. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - March 15, 2017 Category: Respiratory Medicine Source Type: research

Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy
We examined the immunomodulatory activity of Pidotimod (PDT), a synthetic dipeptide molecule in adult patients hospitalized for CAP. Sixteen patients with a diagnosis of CAP and a PSI score III or IV and/or a CURB-65 0–2 were randomized to receive either levofloxacin 500 mg b.i.d. alone or levofloxacin plus PDT (800mg, 2 daily doses). Blood samples were drawn at baseline (T0), before initiation of therapy, as well as 3 (T3), and 5 (T5) days after initiation of therapy. Immunologic and clinical parameters were analyzed at each time point. Supplementation of antibiotic therapy with PDT resulted in an upregula...
Source: Pulmonary Pharmacology and Therapeutics - March 14, 2017 Category: Respiratory Medicine Source Type: research

Can the response to Omalizumab be influenced by treatment duration? A real-life study
Conclusion In real-life, the positive Omalizumab response remained stable for over 60 months. Long term Omalizumab treatment may lead to a discontinuation of some associated medications and to a slowing down of FEV1 decline. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - March 14, 2017 Category: Respiratory Medicine Source Type: research

Effects of early administration of acetazolamide on the duration of mechanical ventilation in patients with chronic obstructive pulmonary disease or obesity-hypoventilation syndrome with metabolic alkalosis. A randomized trial
Conclusions Among patients with MA and COPD or OHS, early treatment with ACTZ did not shorten significantly the duration of MV compared with placebo. Trial registry clinical.trials.gov; NCT01499485; URL: www.clinicalrials.gov. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - March 8, 2017 Category: Respiratory Medicine Source Type: research

Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial
Conclusions Statin use is not associated with a beneficial effects on all cause, CV, non CV mortality and hospitalization in patients with coexistent chronic HF and history of COPD. ClinicalTrials.gov Identifier: NCT00336336 (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - March 3, 2017 Category: Respiratory Medicine Source Type: research

The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis
Conclusions The importance of early and accurate diagnosis of IPF cannot be underestimated and it is the duty of all healthcare professionals to be vigilant to the symptoms of IPF and to involve a multidisciplinary team in diagnosing and managing IPF early in the course of disease. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - March 1, 2017 Category: Respiratory Medicine Source Type: research

Methacholine challenge tests to demonstrate therapeutic equivalence of terbutaline sulfate via different Turbuhaler ® devices in patients with mild to moderate asthma: Appraisal of a four-way crossover design
Conclusions Bronchoprotection using a standardised methacholine challenge model proved to be an effective design to elucidate therapeutic equivalence between devices in patients with mild-to-moderate asthma. The findings indicate that patients may switch from one type of Turbuhaler® to the other without adjustment of therapy. Moreover, they show the robustness and utility of this study design and its suitability for investigating therapeutic equivalence. EudraCT Number 2014-001457-16. Clinicaltrials.gov identifier NCT02322788. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - February 21, 2017 Category: Respiratory Medicine Source Type: research

Do cystic fibrosis patients on azithromycin need electrocardiogram monitoring?
Publication date: Available online 17 February 2017 Source:Pulmonary Pharmacology & Therapeutics Author(s): Rachel Sharpton, Mario Cazzola (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - February 18, 2017 Category: Respiratory Medicine Source Type: research

Advances in mechanisms and management of chronic cough: The Ninth London International Cough Symposium 2016
Publication date: Available online 16 February 2017 Source:Pulmonary Pharmacology & Therapeutics Author(s): Kian Fan Chung At the Ninth London International Cough Symposium held in June 2016, advances in chronic cough were presented. Chronic cough has been labelled as a cough hypersensitivity syndrome (CHS) with neuroinflammatory mechanisms likely to be the underlying mechanisms. The concept is that there is a stage of peripheral sensitisation induced by inflammatory factors setting up the scene for a central component that can be visualised by functional magnetic resonance imaging. There has also been progress in...
Source: Pulmonary Pharmacology and Therapeutics - February 17, 2017 Category: Respiratory Medicine Source Type: research

Mastery of pMDI technique, asthma control and quality-of-life of children with asthma: A randomized controlled study comparing two inhaler technique training approaches
Conclusions The TH improved the inhalation flow through the pMDI close to the ideal needed for adequate lung deposition. Both methods equally enhanced the children's mastery of pMDI use. This was reflected on better AC and QoL. Accessibility to TH might help maintaining the good inhaler use and decreasing regular VC. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - February 17, 2017 Category: Respiratory Medicine Source Type: research

Effect of tobacco and electronic cigarette use on cough reflex sensitivity
Publication date: Available online 6 February 2017 Source:Pulmonary Pharmacology & Therapeutics Author(s): Peter V. Dicpinigaitis Multiple previous studies have shown that otherwise healthy tobacco cigarette smokers have suppressed cough reflex sensitivity compared with nonsmokers and furthermore, that smoking cessation, even after years of tobacco use, leads to prompt enhancement of cough reflex sensitivity. Thus, cough reflex sensitivity is demonstrated to be a dynamic phenomenon, responding to the presence or absence of influences such as tobacco smoke. These studies, however, were unable to identify whether it...
Source: Pulmonary Pharmacology and Therapeutics - February 7, 2017 Category: Respiratory Medicine Source Type: research

Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
Conclusions Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients with late versus early-onset asthma. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - February 1, 2017 Category: Respiratory Medicine Source Type: research

Effect of calcium channel blockers evaluated by cardiopulmonary exercise testing in idiopathic pulmonary arterial hypertension responding to acute pulmonary vasoreactivity testing
Conclusions Ventilatory efficiency in patients with VR-IPAH is better than that in patients with VNR-IPAH. CCB can improve aerobic capacity and ventilatory efficiency during exercise in patients with VR-IPAH. Clinical trial registration number: ClinicalTrials.gov:NCT02061787. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - February 1, 2017 Category: Respiratory Medicine Source Type: research

Central mechanisms of airway sensation and cough hypersensitivity
Publication date: Available online 27 January 2017 Source:Pulmonary Pharmacology & Therapeutics Author(s): Alexandria K. Driessen, Alice E. McGovern, Monica Narula, Seung-Kwon Yang, Jennifer A. Keller, Michael J. Farrell, Stuart B. Mazzone The airway sensory nervous system is composed of two anatomically distinct processing pathways that allow for the production of respiratory reflexes and voluntary evoked respiratory behaviours in response to sensing an airway irritation. Disordered sensory processing is a hallmark feature of many pulmonary disorders and results in the development of cough hypersensitivity syndro...
Source: Pulmonary Pharmacology and Therapeutics - January 28, 2017 Category: Respiratory Medicine Source Type: research

Obituary for Dr Dom Spina (25/11/62 –5/12/16)
Publication date: February 2017 Source:Pulmonary Pharmacology & Therapeutics, Volume 42 (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 27, 2017 Category: Respiratory Medicine Source Type: research

The burden of obesity in asthma and COPD: Role of adiponectin
Publication date: Available online 20 January 2017 Source:Pulmonary Pharmacology & Therapeutics Author(s): Andrea Bianco, Ersilia Nigro, Maria Ludovica Monaco, Maria Gabriella Matera, Olga Scudiero, Gennaro Mazzarella, Aurora Daniele The influence of obesity on development, severity and prognosis of both asthma and COPD is attracting growing interest. The impact of obesity on the respiratory system ranges from structural modifications (decline of total lung capacity) to humoral alterations. Adipose tissue strongly contributes to the establishment of an inflammatory state being an important source of adipokines. Am...
Source: Pulmonary Pharmacology and Therapeutics - January 21, 2017 Category: Respiratory Medicine Source Type: research

Using pharmacokinetic modelling to improve prescribing practices of intravenous aminophylline in childhood asthma exacerbations
Conclusion PBPK software modelling correlates well with clinical data. Current aminophylline iv loading dosage recommendations achieve levels <10 mg/l in 70% of children. Routine TDM may need altering as low risk of toxicity (>20 mg/l). (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 18, 2017 Category: Respiratory Medicine Source Type: research

IL-4R suppresses airway inflammation in bronchial asthma by inhibiting the IL-4/STAT6 pathway
Conclusion Our results demonstrate that IL-4R can suppress airway inflammation in bronchial asthma by inhibited the IL-4/STAT6 pathway, which may provide a new therapeutic approach for the treatment of bronchial asthma. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 17, 2017 Category: Respiratory Medicine Source Type: research

Beta-2-adrenoreceptor polymorphism at position 16 determines the clinical severity of chronic obstructive pulmonary disease
Publication date: Available online 16 January 2017 Source:Pulmonary Pharmacology & Therapeutics Author(s): Justyna Emeryk-Maksymiuk, Andrzej Emeryk, Paweł Krawczyk, Kamila Wojas-Krawczyk, Janusz Milanowski The Arg/Arg homozygosity at codon 16 of the beta-2-adrenoreceptor (ADRB2) gene has been thought to predispose asthma patients to a poorer therapeutic response to beta-2-mimetics, or to worse control of the disease. In contrast, the results of the studies analysing the effect of ADRB2 polymorphisms on the response to beta-2-adrenoreceptor agonists in chronic obstructive pulmonary disease (COPD) patients are spar...
Source: Pulmonary Pharmacology and Therapeutics - January 17, 2017 Category: Respiratory Medicine Source Type: research

Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS
Conclusions and implications In summary, this study shows that JAK inhibition ameliorates inhaled LPS-induced airway inflammation in rats, suggesting that at least JAK/STAT3 signalling is involved in the establishment of the pulmonary neutrophilia induced by LPS. JAKs inhibitors should be further investigated as a potential therapy for respiratory inflammatory diseases. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 11, 2017 Category: Respiratory Medicine Source Type: research

Which treatment for obstructive airway disease: The inhaled bronchodilators
Publication date: Available online 9 January 2017 Source:Pulmonary Pharmacology & Therapeutics Author(s): Fabio Perrotta, Filomena Mazzeo, Francesco Saverio Cerqua (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 10, 2017 Category: Respiratory Medicine Source Type: research

Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study
Conclusions Overall, this study provides reassurance over the cardiovascular safety of extrafine BDP/FF, both in a DPI and a pMDI formulation. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 6, 2017 Category: Respiratory Medicine Source Type: research

MiR-23b controls TGF- β1 induced airway smooth muscle cell proliferation via direct targeting of Smad3
Conclusions MiR-23b may function as an inhibitor of asthma airway remodeling by suppressing ASMCs proliferation via direct targeting of Smad3. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 4, 2017 Category: Respiratory Medicine Source Type: research

Pharmacokinetics of tiotropium administered by Respimat ® in asthma patients: Analysis of pooled data from phase II and III clinical trials
This report presents a combined analysis of tiotropium plasma and urine pharmacokinetics at steady state from 8 Phase II/III clinical trials in asthma and delineates the effects of patient characteristics on systemic exposure based on the parameters fe0-24,ss (fraction of dose excreted unchanged in urine over 24 h post-dose at steady-state) and dose-normalized AUCtau,ss and Cmax,ss. Pharmacokinetics were also compared between asthma and COPD, incorporating data from 3 COPD Phase II/III clinical trials. Tiotropium pharmacokinetics in asthma were dose-proportional up to 5 μg dosed once daily. The following facto...
Source: Pulmonary Pharmacology and Therapeutics - December 28, 2016 Category: Respiratory Medicine Source Type: research

Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: A patient's “Q and A” approach
Publication date: February 2017 Source:Pulmonary Pharmacology & Therapeutics, Volume 42 Author(s): Argyris Tzouvelekis, Vasilios Tzilas, Spyridon Papiris, Vassilis Aidinis, Demosthenes Bouros Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, debilitating disease of unknown etiology that leads to death nearly half of the patients within 3–3.5 years. The past 15 years, the scientific community has made tremendous progress towards standardized diagnostic and prognostic algorithms that led to the generation of the 2011 ATS/ERS/JRS/ALAT guidelines. The latest guidelines provided us with fundamental d...
Source: Pulmonary Pharmacology and Therapeutics - December 19, 2016 Category: Respiratory Medicine Source Type: research

Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis A patient “Q and A” approach
Publication date: Available online 12 December 2016 Source:Pulmonary Pharmacology & Therapeutics Author(s): Argyris Tzouvelekis, Vasilios Tzilas, Spyridon Papiris, Vassilis Aidinis, Demosthenes Bouros Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, debilitating disease of unknown etiology that leads to death nearly half of the patients within 3–3.5 years. The past 15 years, the scientific community has made tremendous progress towards standardized diagnostic and prognostic algorithms that led to the generation of the 2011 ATS/ERS/JRS/ALAT guidelines. The latest guidelines provided us with fund...
Source: Pulmonary Pharmacology and Therapeutics - December 13, 2016 Category: Respiratory Medicine Source Type: research

Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD — A randomised, multicentre, crossover trial
Conclusions Glycopyrronium was superior to tiotropium in terms of early bronchodilation. Although both glycopyrronium and tiotropium showed similar improvements in static lung volume parameters, glycopyrronium reduced specific airway resistance faster than tiotropium, which could in part explain the earlier FEV1 response seen with glycopyrronium. Trial registration ClinicalTrials.gov NCT01922271. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 10, 2016 Category: Respiratory Medicine Source Type: research

Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma
Publication date: Available online 22 November 2016 Source:Pulmonary Pharmacology & Therapeutics Author(s): Makoto Yoshida, Yasuko Kaneko, Akiko Ishimatsu, Masashi Komori, Tomoaki Iwanaga, Hiromasa Inoue The effects of tiotropium, an inhaled long-acting muscarinic antagonist, on lung function were investigated in current smokers and nonsmokers with asthma treated with inhaled corticosteroids (ICSs) and other asthma controllers: inhaled long-acting β2 agonists, leukotriene receptor antagonists, and/or theophylline. We conducted a double-blind, placebo-controlled study of an inhaled single dose of tiotropium in...
Source: Pulmonary Pharmacology and Therapeutics - November 22, 2016 Category: Respiratory Medicine Source Type: research

A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD
Conclusions FF/VI combination was associated with a decrease of the rate of COPD exacerbations, without affecting mortality or cardiovascular outcomes in patients with moderate to severe stable COPD. Also, the use of FF was associated with an increased risk of pneumonia. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 16, 2016 Category: Respiratory Medicine Source Type: research

Biochemical and functional characterization of glycosaminoglycans released from degranulating rat peritoneal mast cells: Insights into the physiological role of endogenous heparin
In conclusion, we have shown that rat peritoneal mast cells contain a mixture of GAGs that possess anticoagulant and anti-inflammatory properties. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 3, 2016 Category: Respiratory Medicine Source Type: research

The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxis
Conclusions BAY 60-2770 reduces airway eosinophilic inflammation and rescue the sGC levels. In human eosinophils under oxidized conditions, BAY 60-2770 elevates the cGMP levels causing cell chemotaxis inhibition. BAY 60-2770 may reveal a novel therapeutic target for asthma treatment. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 3, 2016 Category: Respiratory Medicine Source Type: research

Impact of statins on ALI/ARDS: A meta-analysis
Conclusion The results did not show that statins had effects on mortality and ventilator-free days among ALI/ARDS patients. However, this meta-analysis is limited by the number of RCTs included. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Effect of tiotropium on mucus hypersecretion and airway clearance in patients with COPD
Conclusions Tiotropium decreases symptoms associated with sputum in COPD patients, an effect that may be related to the inhibition of airway mucus hypersecretion and improvement of airway mucociliary clearance. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Nefopam, a non-opioid analgesic, does not alleviate experimental work/effort dyspnoea in healthy humans: A randomised controlled trial
Conclusions In this study, nefopam did not exhibit any effects on dyspnoea. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Targeted drug delivery to emphysematous lungs: Inhibition of MMPs by doxycycline loaded nanoparticles
Publication date: August 2016 Source:Pulmonary Pharmacology & Therapeutics, Volume 39 Author(s): Vaideesh Parasaram, Nasim Nosoudi, Renee J. LeClair, Andrew Binks, Naren VyavahareGraphical abstract (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma
Conclusions In the general study population, no improvement in lung function was observed with QAW039. However, a subgroup analysis revealed that patients with greater severity of airflow limitation (FEV1 < 70%) had improved lung function and asthma control when treated with QAW039. QAW039 also demonstrated a favorable safety profile. Trials registration ClinicalTrials.gov NCT01253603. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Onset of action of budesonide/formoterol Spiromax ® compared with budesonide/formoterol Turbuhaler® in patients with COPD
Publication date: August 2016 Source:Pulmonary Pharmacology & Therapeutics, Volume 39 Author(s): Mario Cazzola, Josuel Ora, Alessanda Di Paolo, Ermanno Puxeddu, Luigino Calzetta, Paola Rogliani Budesonide/formoterol (BF) is available in two delivery systems, the dry powder inhaler (DPI) Turbuhaler and a pressurized metered dose inhaler (pMDI) for use in patients with asthma or chronic obstructive pulmonary disease (COPD). Spiromax DPI was recently developed as an alternative to Turbuhaler DPI. In the present study, we examined whether there is a difference in the onset of bronchodilatation between BF 320/9 &m...
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Corrigendum to “Aminophylline increases respiratory muscle activity during hypercapnia in humans” [Pulm. Pharmacol. Ther. (2015) 96–101]
Publication date: Available online 28 September 2016 Source:Pulmonary Pharmacology & Therapeutics Author(s): Masanori Yokoba, Tsuyoshi Ichikawa, Akira Takakura, Naohito Ishii, Yoshifumi Kurosaki, Yuya Yamada, Tomoaki Tsukushi, Noriyuki Masuda, Paul A. Easton, Masato Katagiri (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Evaluation of adiponectin profile in Italian patients affected by obstructive sleep apnea syndrome
In conclusion, our results strongly suggest a role for Acrp30 oligomerization in OSAS; in fact, the down-regulation of Acpr30 and its HMW oligomers seems to be correlated to illness status independently of concomitant presence of obesity. In addition, this reduction is mainly due to the high-weight oligomers of Acrp30 suggesting a functional role of this adipokine in OSAS. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Conclusions The rank of effectiveness emerging from this meta-analysis represents an indirect indicator of potential differences between currently approved doses of pirfenidone and nintedanib. Direct comparisons are necessary to assess this matter, and well designed bench-to-bedside studies would permit to understand the potential of combined, sequential, or adjunctive treatment regimens in which perhaps NAC may have a role for specific clusters of IPF patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Antitussive effect of carcainium chloride in patients with chronic cough and idiopathic interstitial pneumonias: A pilot study
Conclusion The results of this exploratory study indicate that nebulised VRP700 improved cough and quality of life in hospitalised IIP patients with no significant side effects. A larger trial is warranted to assess these promising results. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Efficacy of tranexamic acid in haemoptysis: A randomized, controlled pilot study
Conclusion TA decreases severity of haemoptysis and can be used as a bridging therapy in acute haemoptysis before definitive intervention can be under taken. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 – A potential oral treatment for tuberculosis
Publication date: October 2016 Source:Pulmonary Pharmacology & Therapeutics, Volume 40 Author(s): Gurleen Kour, Anil Kumar, Parvinder Pal Singh, Sumit Sharma, Asha Bhagat, Ram A. Vishwakarma, Zabeer Ahmed New compounds against tuberculosis are urgently needed to combat the crisis of drug resistance in tuberculosis (TB). We have identified a nitrodihydroimidazooxazole analog, IIIM-019 as a new anti-tubercular agent with a MIC of 0.23 μM against H37Rv. Physicochemical properties, in-vitro pharmacokinetics and in-vivo multiple-doses pharmacokinetics were studied for the compound. In silico physicochemical par...
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension
Conclusion Transitioning patients from parenteral to inhaled prostacyclin therapy can be safely accomplished in specialized centers over a 48–72 h period. Patient preference was overwhelming the most prevalent reason for transition. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Effect of polyunsaturated fatty acids (PUFAs) on airway epithelial cells' tight junction
Publication date: October 2016 Source:Pulmonary Pharmacology & Therapeutics, Volume 40 Author(s): Maliheh Ghadiri, Mariam Mamlouk, Patrick Spicer, Wolfgang Jarolimek, Georges E.R. Grau, Paul M. Young, Daniela Traini (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

The effects of inhaled respiratory drugs on the risk of stroke: A nested case-control study
Publication date: October 2016 Source:Pulmonary Pharmacology & Therapeutics, Volume 40 Author(s): Chang-Hoon Lee, Seongmi Choi, Eun Jin Jang, Dong-Wook Kim, Ho Il Yoon, Yun Jung Kim, Jimin Kim, Jae-Joon Yim, Deog Kyeom Kim Although there have been concerns that inhaled long-acting muscarinic antagonists increase the risk of stroke, controversies exist. We investigated whether respiratory drugs including long-acting muscarinic antagonists are associated with the risk of stroke. A nested case-control study using the nationwide insurance claims database of the Health Insurance Review and Assessment Service (Seoul, Re...
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients
Publication date: October 2016 Source:Pulmonary Pharmacology & Therapeutics, Volume 40 Author(s): D. Singh, B. Leaker, M. Boyce, M.A. Nandeuil, S. Collarini, F. Mariotti, D. Santoro, P.J. Barnes CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of obstructive lung diseases. The efficacy and safety of CHF6001 were investigated in a double blind, placebo controlled, 3-way cross-over study using the allergen challenge model. Thirty-six atopic asthmatics who were not taking inhaled corticosteroids and who demonstrated a late asthmatic response (LAR) to inhaled allergen at scre...
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research

Short-term versus longer duration of glucocorticoid therapy for exacerbations of chronic obstructive pulmonary disease
Conclusion These data show that short-term glucocorticoid is as effective as and possibly safer than longer duration. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2016 Category: Respiratory Medicine Source Type: research